Gufic Biosciences Ltd

Financial Performance

• Q1 FY27 revenue: INR 260.8 crores; vs Q1 FY26: INR 226.9 crores.
• Q1 EBITDA: INR 47.2 crores; margin 18.09%.
• Q1 PBT: INR 30.1 crores; margin 11.56%.
• Q1 PAT: INR 22.46 crores; margin 8.61%.
• Q4 FY26: revenue INR 252.1 crores; EBITDA 44.7; PBT 27.6; PAT 20.6.

Operations & Capacity

• Indore plant: capacity utilization rising; validations complete; depot and microsphere suites nearing operation.
• Indore: 6 lyophilizers; 4 x 100,000-vial lines; 2 x 44,000-vial lines.
• Depot and liposomal lines to be added on one lyophilizer for capacity expansion.
• EU export certificate: Navsari certified; Indore certificate expected in 1-2 months.
• Indore capacity utilization targeted at 40%–45% with current product mix.
• Maximum revenue with current investment: INR 800–1,200 crores (Indore).

GLP-1 & International Strategy

• GLP-1: purely CMO; no front-end revenue; revenue residual in Q1 via Hetero.
• Hetero permission for semaglutide obtained in May 2026; traction expected from Q2.
• Canada fillers tie-up with Revanesse Prollenium; India launch likely by Dec/Jan; revenue from Q2.
• International model shifting to front-end with own field force; potential margins 40–50% in some markets.

Q&A Highlights

• Europe export growth and 8-country registrations; 5 presentations cleared in a single therapy area.
• Indore utilization and export volumes rising; U.S. submissions from partner sites anticipated.
• Filler market in India ~INR 200 crores; potential to move toward toxin+filler leadership in 3–5 years.
• GLP-1 traction to accelerate in Q2–Q3; full GLP-1 revenue remains as CMO only.
• Company targets 15–20% YoY growth; minimum 15% YoY growth commitment.

Outlook & Guidance

• Revenue growth guidance: 15%–20% YoY for FY27.
• No front-end plans for GLP-1; GLP-1 revenue to be captured as CMO.
• Indore capacity expansion and product mix changes expected to drive operating leverage by mid-FY28.

Meeting Details

• Earnings conference call held on August 17, 2026 at 04:30 p.m.
• Type and mode: earnings conference call; audio recording.
• Organiser: Gufic Biosciences Limited.
• Recording availability: audio recording uploaded on company website; transcript to follow.

Participants

• Key participants: management roles not disclosed in the filing.

Purpose

• Purpose: earnings results discussion and investor interaction.

Additional Notes

• Transcript will be submitted in due course; no links provided.

Business Overview

• Integrated pharma group focused on lyophilized injectables and CDMO services.
• Indore/Navsari facilities target regulated markets and NDDS development.
• Strategic pivot to IP-owned international model with MA control via Gufic Ireland.

Operational Highlights

• Indore plant produced first batch in Oct 2024; qualification progressing.
• IQ/OQ completed; PQ and media fills completed across lines.
• EU GMP audit completed; UK MHRA audit expected; US FDA filings ongoing.
• 203 State FDA approvals; 20+ vendor audits; 40 tech transfers completed.
• Q1 FY27 revenue 260.8 Cr; EBITDA 47.2 Cr; PAT 22.0 Cr.

Financial Performance

• FY26 total income 943.1 Cr; EBITDA 152.9 Cr; PAT 63.1 Cr.
• FY26 EBITDA margin 16.21%; PAT margin 6.69%.
• FY26 cash from operations 44.1 Cr; cash end 60.3 Cr.
• Mar-26 equity 664.2 Cr; total borrowings 385.1 Cr; total assets 1341.6 Cr.

Capital Structure & Liquidity

• Debt: borrowings ~385 Cr; liquidity supported by 60.3 Cr cash at Mar-26.
• Equity: total equity ~664 Cr; regulatory MA structure via EU pathway.
• Approvals across eight countries in Q1 FY27; EU MA via Gufic Ireland.

Strategic Priorities & Outlook

• Pivot to IP-owned, injectable-led international model with MA control.
• Scale Indore to de-bottleneck Navsari; add regulated products.
• Target 5-10% market share in identified geographies; expand therapy basket.
• Increase licensing/tech-transfer deals; partnerships with Turkey, Brazil, India.
• R&D focus on peptides, NDDS, and in-house API self-reliance.

Risks & Governance

• EU GMP certification for new Indore site awaiting; regulator audits scheduled.
• Regulatory delays and manufacturing complexity pose execution risks.
• Forward-looking statements subject to approvals; macro/regulatory shifts.
• EU MA ownership via Gufic Ireland supports EU market access.

Target & business

• Proposed subsidiary in the Philippines: Gufic Philippines Inc, to be incorporated subject to regulatory approvals.
• Industry: Pharmaceuticals; activities include marketing, sale, distribution, and IP rights management.
• Holding company: Gufic Biosciences Limited will own the subsidiary.
• Geographic focus: expansion of Gufic's Philippines presence for its products.

Transaction details

• Investment will be by cash subscription to the subsidiary's equity capital.
• Cost: up to USD 250,000, or equivalent Philippine Peso.
• The listed company will hold approximately 99.99% equity; remaining shares to directors.

Ownership & related party

• Related party transaction: investment within the same corporate group as the parent.
• Holding structure: Gufic Biosciences Limited will be the parent of the subsidiary.

Regulatory & timeline

• Approvals required include SEC Philippines registration and applicable licenses.
• Incorporation to occur within 12 months from board approval.
• Compliance with foreign exchange and overseas investment regulations.

Background & rationale

• Background: target will market, sell, and distribute pharmaceutical products in the Philippines.
• Rationale: expand Philippines footprint and manage IP rights locally.
• Incorporation date is not yet fixed; timeline is within 12 months.

Philippines subsidiary

• Target: Gufic Philippines Inc., Philippines-based pharma marketing and distribution subsidiary.
• Size: not disclosed.
• Related party: yes; Gufic Biosciences Limited to hold ~99.99%.
• Industry: Pharmaceuticals (healthcare).
• Rationale: expand presence in the Philippines, manage IP rights, support growth.
• Regulatory approvals: SEC Philippines incorporation, pharma licenses/registrations, FX/foreign investment compliance.
• Timeline: incorporation within 12 months subject to formalities.
• Consideration: cash subscription to equity share capital.
• Cost: up to USD 250,000 (PHP equivalent).
• Shareholding: ~99.99% post-subscription.
• Background: proposed subsidiary to market/distribute pharma products in Philippines, and hold IP rights; incorporation planned within 12 months.

Financial results and subsidiary investment

• Unaudited standalone and consolidated results for quarter ended 30-Jun-2026 approved; Limited Review Report included.
• Incorporation of Gufic Philippines Inc. approved; investment by cash subscription up to USD 250,000.
• Proposed ownership ~99.99% of the subsidiary.
• Subject to completion of applicable statutory and regulatory formalities.

Overview

• Standalone BRSR for FY2025-26; pharmaceutical manufacturer and marketer.
• Exports accounted for 23.07% of turnover.
• Operations include 3 domestic plants and 31 total offices.

Key ESG Risks & Opportunities

• Talent development and succession planning to mitigate shortages.
• Structured EHS management with hazard assessments, audits and training.
• Supply chain resilience via supplier evaluations and Code of Conduct.
• Governance: Code of Conduct, anti-bribery framework, Vigil Mechanism with board oversight.
• Energy and water management: efficiency programs, water recycling, and EPR compliance.
• DPDP Act compliance framework for data privacy.

Governance & Policy Highlights

• Board-approved BR and sustainability policies; COO reports to Board.
• Anti-corruption policy with zero tolerance.
• Whistleblower, Vigil Mechanism, Code of Conduct, Supplier Code of Conduct in place.
• No external BRRSR assurance; no material penalties in FY2025-26.

Social Responsibility & Workforce

• Total workforce: 1,954 employees and 949 workers.
• Board female representation: 16.7%; KMP female: 50%.
• Permanent employee turnover: 20.7% in FY2025-26.
• LTIFR: employees 0.62; workers 2.25.
• 100% health insurance for employees; group mediclaim.
• 100% BR-related training for Board/KMP and workforce.
• CSR initiatives include tree planting and community healthcare/education programs.

Environmental Performance

• Scope 1+2 GHG: 25,463.99 MTCO2e; intensity 2.71 per turnover.
• Non-renewable energy: 211,633.58 GJ; intensity 22.50 per turnover.
• Water withdrawal: 108,177 KL; water intensity 11.50 per turnover.
• ZLD implemented at Navsari and Indore; water recycling in processes.
• Waste: total 121.16 t; recycled 76.29; incineration 18.29; landfilling 15.40; other 6.73.
• Certifications: ISO 9001/14001/45001; WHO-GMP; CDSCO approvals.
• Plastic waste EPR with CPCB registration; co-processing where feasible.
• Energy optimization projects include briquette boilers and advanced HVAC.

Stakeholder Engagement & Complaints

• Key stakeholder groups: employees, investors, customers, suppliers, communities.
• Investors engaged quarterly; employees ongoing; communities ongoing; multiple channels used.
• 29 complaints filed in FY2025-26; 0 pending; mechanism includes IR, website, and ODR portal.
• Community grievances: no significant issues reported.

Other Notable Metrics

• Related party transactions: purchases 0.08%; sales 0.62%; top 10 dealers 49.64%.
• Inputs from critical suppliers sustainably sourced >90%.
• Cybersecurity: data privacy framework in place; no data breaches recorded.
• No unions; right to association acknowledged; 100% accessibility for differently-abled.